ALNY Stock: Alnylam Pharmaceuticals, Inc. Stock Price, Analysis & Insights
Get live ALNY stock price $296.67, comprehensive Alnylam Pharmaceuticals, Inc. stock analysis, charts, news, and expert forecast. Real-time ALNY stock data and investment insights.
Loading chart data...
Alnylam Pharmaceuticals, Inc. (ALNY) Overview
Alnylam Pharmaceuticals, Inc. (ALNY) is a publicly traded company in the Healthcare sector , specifically within the Biotechnology industry . As of the latest trading session, ALNY trades at $296.67 with a market capitalization of 39.61B . Over the past 52 weeks, ALNY has traded between $283.10 and $495.55 , with the current price positioned at approximately 6% of this range . The stock current...
Key Takeaways
- Operates in the Healthcare sector (Biotechnology)
- Market cap: 39.61B
- Current price: $296.67
- 52-week range: $283.10 - $495.55
- P/E ratio: 74.73
Investment Score
A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.
Score unavailable for this asset.
0-39
Defensive posture
40-54
Mixed / wait for confirmation
55-69
Constructive setup
70-100
Attractive zone
Total Score
Value
Cheapness vs fundamentals and cash generation
Quality
Durability of profitability and balance sheet
Momentum
Price trend strength and persistence
Company Overview
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline ...
Company Information
- CEO
- Yvonne L. Greenstreet
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2230
Contact Information
- Website
- https://www.alnylam.com
- Address
- 675 West Kendall Street
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Growth-oriented company with premium valuation (P/E: 74.7)
✓ Lower volatility stock (Beta: 0.27) may provide portfolio stability
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Alnylam Pharmaceuticals, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for mid-cap stocks
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Alnylam Pharmaceuticals, Inc.
- ⚠Investors should consider how Alnylam Pharmaceuticals, Inc. fits within their overall portfolio allocation
- ⚠Premium valuation (P/E: 74.7) requires strong growth to justify
Market Cap
39.61B
P/E Ratio (TTM)
74.73
Beta
0.27
Data Sources & Methodology
Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.
Related Stocks
Compare ALNY with peer companies:
- Price
- $883.45
- Market cap
- 54.67B
- Price
- $150.12
- Market cap
- 54.39B
- Price
- $217.28
- Market cap
- 50.89B
- Price
- $295.80
- Market cap
- 78.25B
- Price
- $281.19
- Market cap
- 54.71B
- Price
- $86.47
- Market cap
- 49.79B
- Price
- $567.39
- Market cap
- 44.76B
- Price
- $610.65
- Market cap
- 62.91B
- Price
- $166.63
- Market cap
- 27.19B
- Price
- $82.56
- Market cap
- 34.61B
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.